What side effects are associated with this type of intervention?

Highly active antiretroviral therapy (HAART) is a common treatment for HIV/AIDS. Known side effects of HAART can include nausea, vomiting, diarrhea, fatigue, and headaches. Some patients may also experience more severe side effects such as liver toxicity, kidney problems, and changes in body fat distribution. It is important for patients to work closely with their healthcare providers to manage these side effects and adjust treatment as necessary.

What prior FDA approvals exist?

The FDA has approved numerous antiretroviral drugs for the treatment of HIV/AIDS, including nucleoside reverse transcriptase inhibitors (NRTIs) like zidovudine (AZT) and lamivudine (3TC), non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as efavirenz, protease inhibitors (PIs) like ritonavir, and integrase strand transfer inhibitors (INSTIs) such as raltegravir. Combination therapies, such as Atripla (efavirenz/emtricitabine/tenofovir) and Truvada (emtricitabine/tenofovir), have also been approved to enhance treatment efficacy and adherence. These treatments are essential in managing HIV and improving patient outcomes, particularly when integrated with comprehensive care strategies addressing health-harming legal needs.

What other types of research exist?

Promising novel alternatives to Legal Aid for HIV/AIDS patients in 2024 include: 1) Medical-Legal Partnerships (MLPs) that embed legal services within healthcare settings to address social determinants of health; 2) Comprehensive provider training programs to increase awareness and management of health-harming legal needs; 3) Co-location of legal and healthcare services to facilitate seamless access to both; and 4) Use of digital platforms to provide remote legal consultations and support, ensuring broader reach and accessibility.

← Back to Search

Legal Aid and Training for HIV Care

N/A

Recruiting

Research Sponsored by University of Central Florida

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

18 years or older

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to improve HIV care for people who have been in prison by combining legal help with medical care. The program trains healthcare and legal staff to work together and provides integrated services to remove barriers to treatment.

Who is the study for?

This trial is for individuals who were previously incarcerated and are living with HIV/AIDS. It aims to explore how legal aid can improve their health outcomes. Participants should be interested in receiving legal assistance and willing to engage with healthcare providers trained in medical-legal partnerships.

What is being tested?

The study tests the effect of providing legal aid on HIV care for those formerly incarcerated, alongside a training program for healthcare providers. The goal is to see if these interventions help patients stay on track with their HIV treatment and improve communication among caregivers.

What are the potential side effects?

Since this trial involves non-medical interventions like legal aid and provider training, traditional physical side effects are not applicable. However, participants may experience stress or anxiety related to discussing legal issues or personal health information.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

HIV viral load using polymerase chain reaction (PCR)

Secondary study objectives

Quality of Life checklist

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: CTI-MLP assessmentExperimental Treatment1 Intervention

To assess the feasibility and acceptability of a comprehensive critical-time intervention medical legal partnership (CTI-MLP) approach to improve HIV care continuum outcomes among formerly incarcerated individuals and determine the most efficient mechanisms for CTI-MLP delivery

Group II: CTI-MLP approachExperimental Treatment1 Intervention

To finalize protocols and a medical-legal partnership training manual for health and social service providers at Hope and Help Inc.

0 / 1Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for HIV/AIDS involve antiretroviral therapy (ART), which includes several classes of drugs: nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) inhibit the reverse transcriptase enzyme, preventing the conversion of viral RNA into DNA; protease inhibitors (PIs) block the protease enzyme, preventing the maturation of viral proteins; integrase strand transfer inhibitors (INSTIs) inhibit the integrase enzyme, preventing the integration of viral DNA into the host genome; and entry inhibitors prevent the virus from entering host cells. These treatments are crucial for reducing viral load, preventing disease progression, and improving the quality of life for HIV/AIDS patients, which is particularly important in comprehensive care approaches like those studied in the Legal Aid trial.